WASHINGTON--(BUSINESS WIRE)--Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on unanimous passage of S. 3187, the Food and Drug Administration Safety and Innovation Act (FDASIA), by the U.S. House of Representatives: “BIO commends the House of Representatives for its unanimous approval of FDASIA, which includes a reauthorization of the Prescription Drug User Fee Act (PDUFA).
